Iron therapy the way duodenal enterocytes deserve!



IROSPAN® 24/6 is an innovative formula and dosing regimen developed specifically for women to maximize iron absorption and tolerability.

IROSPAN® 24/6 Formulation

Two uniquely different forms of Iron for maximized Absorption

—Ferrous bisGlycinate Chelate

• Absorbed more evenly throughout the entire GI tract and not affected by higher pH.1,2,3

• More resistant to interference from food and liquid substances.1,2,3

—Polysaccharide Iron Complex

• Non-ionic delivery system allows the ionic iron to be delivered to the bloodstream without coming into contact with the stomach or upper GI tract.

—Complex B-vitamins to promote energy

—Irospan® contains Formical®, a patented source of calcium formate.

24/6 Dosing Regimen

Twenty four days of combination iron therapy with ascorbic acid providing 130 mg of elemental iron

• Ascorbic acid promotes efficient absorption by pushing iron into duodenal enterocyte cells, blocking binding phytates, tannins, and polyphenols that normally interfere with iron absorption.4-5

Six days of succinic acid therapy

• Stimulates iron transmission by pulling iron from intestinal enterocyte cells into the bloodstream, which promotes iron absorption even when oral iron is not being administered.2,4

Benefits of 24/6 therapy

Maximum Iron absorption… Highest absorption of iron has been shown to occur in the first 20-24 days of therapy7

• Active Iron is only administered when the body is capable of absorbing it efficiently7

Fewer Iron related side effects…Research indicates iron absorption decreases after 20-24 days of continuous therapy.7 Continuous iron only therapy may lead to chronic irritation of the epithelial cells lining the gastrointestinal (GI) tract, which may explain common iron related side effects.8

• In addition to enhancing tolerability, the unique regimen and formula promotes continued iron absorption during the 6 day succinic acid period.

Comparable Iron Therapies Report:

• 2-gram hemoglobin increase in first month of therapy, and a 3.5-gram increase by month three

Complementary Iron Formulation for Optimal Result

Unique combination of complementary and easily absorbable irons

Irospan’s dual iron formulations, ferrous bisGlycinate chelate and polysaccharide iron complex, are absorbed in different intestinal sites

Chelated iron has been shown to be absorbed up to 3.4 times more than ferrous sulfate.9

A unique push/pull mechanism promotes superior absorption

The ascorbic acid contained in Irospan® pushes the iron into duodenal cells and blocks substances that interfere with iron absorption. The succinic acid therapy pulls iron from those cells into the bloodstream during the 6 days that iron is not administered.

Research has shown that ascorbic and succinic acids can enhance absorption by 33% and 30%, respectively, without a rise in side effects.4,10

Iron deficiency is the most common known form of nutritional deficiency. Its prevalence is highest among young children and women of childbearing age (particularly pregnant women). In children, iron deficiency causes developmental delays and behavioral disturbances, and in pregnant women, it increases the risk for a preterm delivery and delivering a low-birthweight baby. In the past three decades, increased iron intake among infants has resulted in a decline in childhood iron-deficiency anemia in the United States. For women of childbearing age, iron deficiency has remained prevalent.

IROSPAN® 24/6 Iron / Folic Acid / Supplement Tablets and Succinic Acid Tablets provide a 30 day oral iron supplement therapy

CLINICAL PHARMACOLOGY: Iron is an essential component in the formation of hemoglobin. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport.

Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase.

Vitamin B12 is required for the maintenance of normal erythropoiesis, nucleoprotein and myelin synthesis, cell reproduction and normal growth. Intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of Vitamin B12 from the gastrointestinal tract.

INDICATIONS AND USAGE: IROSPAN® 24/6 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs.

Distributed by: Women’s Choice Pharmaceuticals • Gilbert, AZ 85233 • (877) 774-4949

Formical® is a registered trademark of Nephro-Tech 1, LLC

US Patent #6,528,542, #6,489,361, #6,160,016

IROSPAN® is a registered trademark of Women’s Choice Pharmaceuticals, LLC

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.


1 Garcia-Casal MN, Layrisse M. The effect of change in pH on solubility of iron bis-glycinate chelate and other iron compounds. Arch Latinoam Nutr. 2001;51(suppl 1):35-36.

2 Bovell-Benjamin AC, Viteri FE, Allen LH, Iron absorption from ferrous bisGlycinate and ferric triglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000;71(6):1563-1569.

3 Lynch SR, Stoltzfus RJ, Iron and ascorbic acid: proposed fortification levels and recommended iron compounds. J Nutr. 2003;133:2978S-2984S.

4 Brise H, Hallberg L, Effect of ascorbic acid on iron absorption. Acta Med Scan. 1962;171(suppl 376):51-58.

5 Zijp IM, Korver O, Tijburg LB. Effect of tea and other dietary factors on iron absorption. Crit Rev Food Sci Nutr. 2000;40(5):371-398.

6 Atanasova BD, Li AC, Bjarnason I, Tzatchev KN, Simpson Rj. Duodenal ascorbate and ferric reductase in human iron deficiency. Am J Clin Nutr. 2005;81:130-133.

7 Hallberg L, Norrby A, Solvell L. Oral iron with succinic acid in the treatment of iron deficiency anaemia. Scand J Haematol. 1971;8:104-111.

8 Careddu P, Scotti A. Controlled, double-blind, multicenter clinical trial of iron protein succinylate in the treatment of iron deficiency in children. Int J Clin Pharmocol Ther Toxicol. 1993;31(4):157-169

9 Pineda O. Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17:381-384.

10 Hallberg L, Solvell. Succinic acid as absorption promoter in iron tablets. Acta Med Scand Suppl. 1966;459:23-35.